Associate Professor Michael Hill
Laboratory Scientific Director
- MRC PHRU Director of Laboratories
Associate Professor Mike Hill joined CTSU in 2009 and is the Laboratory Scientific Director of the NDPH Wolfson Laboratories. He has a background in population-based studies and functional studies associated with respiratory and cardiovascular disease. He manages a team of 40 research and technical staff and is responsible for senior strategic oversight of all aspects of laboratory research within NDPH.
Mike works closely with NDPH’s principal investigators, providing central laboratory support for their clinical trials and observational studies ensuring the scientific integrity of the laboratory work.
Research interests include investigating new biochemical markers and validating analytical methods suitable for large-scale research. NDPH Wolfson Laboratories are a UKAS accredited testing laboratory (ISO 17025:2017 No. 2799) with extensive computer automation and a particular expertise in developing reliable high-throughput methods of analysis in clinical chemistry and protein biomarkers.
Previous history: Mike gained his DPhil at the University of Oxford in 1992 and continued his post-doctoral studies at the Nuffield Department of Clinical Medicine, Oxford and The Wellcome Trust Centre for Human Genetics, Oxford. In 1998, he joined the Division of Medicine at University College London where he led a research group.
Genotyping, sequencing and analysis of 140,000 adults from the Mexico City Prospective Study
Ziyatdinov A. et al, (2022)
Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study.
Clarke R. et al, (2022), Atherosclerosis, 354, 15 - 22
Circulating proteins and risk of pancreatic cancer: a case-subcohort study among Chinese adults.
Kartsonaki C. et al, (2022), Int J Epidemiol
Importance of healthy lifestyle factors and ideal cardiovascular health metrics for risk of heart failure in Chinese adults.
Yang R. et al, (2021), Int J Epidemiol
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
HPS3/TIMI55-REVEAL Collaborative Group Writing Committee: None. et al, (2021), Eur Heart J